UnitedHealth Forecast, price target & analysts
UnitedHealth Target price 2026 - Analyst rating & recommendation
UnitedHealth Classifications & Recommendation
UnitedHealth Price Target
| Target Price | $493.50 |
| Price | $376.90 |
| Potential | 30.94% |
| Number of Estimates | 30 |
| 30 Analysts have issued a price target UnitedHealth 2027 . The average UnitedHealth target price is $493.50. This is 30.94% higher than the current stock price. The highest price target is $555.45 47.37% , the lowest is $316.13 16.12% . | |
| A rating was issued by 34 analysts: 27 Analysts recommend UnitedHealth to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the UnitedHealth stock has an average upside potential 2027 of 30.94% . Most analysts recommend the UnitedHealth stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
31 Analysts have issued a sales forecast UnitedHealth 2026 . The average UnitedHealth sales estimate is
This results in the following potential growth metrics:
26 Analysts have issued an UnitedHealth EBITDA forecast 2026. The average UnitedHealth EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
31 UnitedHealth Analysts have issued a net profit forecast 2026. The average UnitedHealth net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
31 Analysts have issued a UnitedHealth forecast for earnings per share. The average UnitedHealth EPS is
This results in the following potential growth metrics and future valuations:
Current UnitedHealth Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Jul 21 2026 |
| Mizuho |
Outperform
➜
Outperform
|
Unchanged | Jul 21 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Jul 20 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 17 2026 |
| Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Jul 17 2026 |
| Keybanc |
Overweight
➜
Overweight
|
Unchanged | Jul 17 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Jul 17 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Jul 21 2026 |
|
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Jul 21 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Jul 20 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 17 2026 |
|
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Jul 17 2026 |
|
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Jul 17 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Jul 17 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
